Dendreon’s Story Of Continuing Slow Growth For Provenge Seems Unconvincing To Wall Street
This article was originally published in The Pink Sheet Daily
Executive Summary
Dendreon’s new CEO has yet to articulate whether he plans large-scale strategic changes to how the company markets Provenge, instead focusing his early comments to investors on deeper penetration of existing accounts and guiding to low-single-digit quarterly sales growth.